Skip to main content

Table 3 Quantitative analysis of DNMT3A R882H in follow-up samples from 6 AML patients

From: Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia

Patient Age/Gender FAB Karyotype Mutations at diagnosis Disease status DNMT3A % NPM1 log FLT3 Ratio Outcome/OS
1 52/F M4 46,XX NPM1 DS 21,45 1^106 0,72 CR/9+
FLT3-ITD CR after CT 16,4 1^-5 0
FLT3-TKD2 CR, day+28 after alloSCT , CDC 0 0 0
DNMT3A CR, day+195 after alloSCT, CDC 0 0 0
2 60/M M2 46,XY, del(9q) NPM1 DS 11,95 1^105   CR/31+
DNMT3A CR after IT 5,8 1^10-2  
CR after CT 0,05 1^10-4  
CR, Platelet ↓ 0,1 1^10-4  
CR 16,5 1^10-5  
CR 30,8 0  
CR 11,3 1^10-4  
CR, day+26 after alloSCT, 98 % DC 0 0  
CR, day+73 after alloSCT (CDC) 0 0  
3 43/F M4 46,XX NPM1 DS 17,9 1^105 0,78 CR/52+
FLT3-ITD CR, day+563 after alloSCT, CDC 0 1^10 -5 0
DNMT3A CR, day+731 after alloSCT, CDC 0 1^10 -4 0
CR, day+1082 after alloSCT, CDC 0 0 0
CR, day+1445 after alloSCT, CDC 0 0 0
4 50/M M4 46,XY NPM1 DS 14,95 1,0^105 0,41 R/17+
FLT3-ITD CR after IT 1,6 1^10-4 0
DNMT3A CR after CT 1,2 1^10-5 0
CR, day+40 after alloSCT, CDC) 0 1^10 -4 0
CR, day+130 after alloSCT, CDC 0,1 0 0
CR, day+217 after alloSCT, CDC 0 0 0
R, day+306 after alloSCT, 10 % DC 9,25 1^10 5 0
R, day+373 after alloSCT, 15 % DC 11,7 1^10 4 0,25
5 50/F 5a 46,XX NPM1 DS 22,15 1^105 0,5 CR/26
FLT3-ITD CR after IT 0,35 1^10-4 0
DNMT3A CR after IT 0,2 1^10-4 0
IDH1 CR after CT 0,1 1^10-4 0
CR after CT 0,05 0 0
CR, day+29 after alloSCT, CDC 0,05 1^10 -4 0
CR, day+71 after alloSCT, CDC 0 1^10 -5 0
R, day+114 after alloSCT, 90 % DC 0,05 1^10 -4 0
CR, day+174 after alloSCT, CDC 0 0 0
CR, day+215 after alloSCT, CDC 0 0 0
6 71/M 5a 46,XY NPM1 DS 12,75 1^104   CR/46+
DNMT3A CR after IT 0,1 1^10-2  
IDH1 CR after CT 0,1 1^10-4  
IDH2 CR after CT 1,65 1^10-4  
CR 0,1 1^10-4  
CR 4,05 1^10-4  
CR 0,5 0  
CR 0 0  
CR 0 1^10-4  
R 2 1^10-2  
R 0,5 1^104  
2.CR 0 1^10-4  
2.CR 0,05 1^10-3  
CR, day+27 after alloSCT, 92 % DC 0 1^10 -4  
CR, day+80 after alloSCT, 60 % DC 0,45 0  
CR, day+91 after alloSCT, 65 % DC 0,15 1^10 -4  
CR, day+208 after alloSCT 14 % DC 1,25 0  
CR, day+279 after alloSCT, CDC 0 0  
CR, day+570 after alloSCT, CDC 0 0  
  1. FAB French–American–British classification systems, DS primary diagnosis, IT induction therapy, CT consolidation therapy, CR complete remission, R Relapse, alloSCT allogeneic stem cell transplantation, CDC complete donor chimerism, DC donor cells
  2. +patient alive at the end of study. Samples after alloSCT are bold